These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3864520)

  • 21. [Monitoring high dose methotrexate therapy (HD MTX) in children with osteosarcoma and computer simulation using a pharmacokinetic model].
    Taljański W; Zimak J; Piekarczyk A
    Med Wieku Rozwoj; 1999; 3(3):343-52. PubMed ID: 10910661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methotrexate-vindesine association in head and neck cancer: modification of methotrexate's hydroxylation in presence of vindesine.
    Bore P; Lena N; Imbert AM; Favre R; Cano JP; Meyer G; Carcassonne Y
    Cancer Chemother Pharmacol; 1986; 17(2):171-6. PubMed ID: 3719898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian estimation and prediction of clearance in high-dose methotrexate infusions.
    Iliadis A; Bachir-Raho M; Bruno R; Favre R
    J Pharmacokinet Biopharm; 1985 Feb; 13(1):101-15. PubMed ID: 3839529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
    Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
    Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison.
    Borsi JD; Schuler D; Moe PJ
    Cancer Chemother Pharmacol; 1988; 22(1):33-5. PubMed ID: 3260832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma.
    Pignon T; Lacarelle B; Duffaud F; Guillet P; Catalin J; Durand A; Monjanel S; Favre R
    Cancer Chemother Pharmacol; 1994; 33(5):420-4. PubMed ID: 8306417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate.
    Breithaupt H; Küenzlen E
    Cancer Treat Rep; 1982 Sep; 66(9):1733-41. PubMed ID: 6956440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
    Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
    Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variability in dose intensity of high-dose methotrexate for nonmetastatic osteosarcoma.
    Leavey PJ; Mantadakis E; Maale G
    Pediatr Hematol Oncol; 2002; 19(7):483-9. PubMed ID: 12217194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I and pharmacology study of continuous-infusion low-dose methotrexate administration.
    Lokich JJ; Curt G
    Cancer; 1985 Nov; 56(10):2391-4. PubMed ID: 4042071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A device for rapid elevation of plasma methotrexate (MTX) concentration and its maintenance in high-dose MTX therapy].
    Miyauchi Y; Mii Y; Morishita T; Miura S; Honoki K; Aoki M; Kido A; Tamai S; Hino M; Nomura Y; Nakanishi E
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):595-9. PubMed ID: 8678518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits after intravenous administration.
    Chen ML; Chiou WL
    J Pharmacokinet Biopharm; 1983 Oct; 11(5):499-513. PubMed ID: 6668556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Urinary beta 2-microglobulin as an indicator for impaired excretion of methotrexate].
    Amino K; Kawaguchi N; Matsumoto S; Manabe J; Ishii Y; Tabata D; Machida M
    Gan To Kagaku Ryoho; 1988 Nov; 15(11):3103-7. PubMed ID: 3056278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate.
    Crom WR; Pratt CB; Green AA; Champion JE; Crom DB; Stewart CF; Evans WE
    J Clin Oncol; 1984 Jun; 2(6):655-61. PubMed ID: 6539365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A pharmacokinetic study on high-dose methotrexate administration--the effects of volume changes of parenteral solutions on the elimination rate].
    Yoshioka S; Tsukamoto T; Nakano M; Oka S; Nakano M; Norimatsu H
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):97-102. PubMed ID: 8291921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose methotrexate with a safe rescue program.
    Decker DA; Edmonson JH; Gilchrist GS; Kovach JS; Offord JR; Taylor WF
    Oncology; 1981; 38(5):262-4. PubMed ID: 6973732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia.
    Evans WE; Stewart CF; Hutson PR; Cairnes DA; Bowman WP; Yee GC; Crom WR
    Drug Intell Clin Pharm; 1982 Nov; 16(11):839-42. PubMed ID: 6959800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose methotrexate for osteosarcoma: toxicity and clinical results.
    Breithaupt H; Küenzlen E
    Oncology; 1983; 40(2):85-9. PubMed ID: 6600827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis.
    Chládek J; Grim J; Martínková J; Simková M; Vanìèková J; Koudelková V; Noièková M
    Br J Clin Pharmacol; 2002 Aug; 54(2):147-56. PubMed ID: 12207634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.